References
Cosman F, Crittenden DB, Adachi JD, Binkley N, Czerwinski E, Ferrari S, Hofbauer LC, Lau E, Lewiecki EM, Miyauchi A, Zerbini CA, Milmont CE, Chen L, Maddox J, Meisner PD, Libanati C, Grauer A (2016) Romosozumab treatment in postmenopausal women with osteoporosis. N Engl J Med 375:1532–1543
Farrier AJ, Sanchez Franco LC, Shoaib A, Gulati V, Johnson N, Uzoigwe CE, Choudhury MZ (2016) New anti-resorptives and antibody mediated anti-resorptive therapy. Bone Joint J 98-B(2):160–165. doi:10.1302/0301-620X.98B2.36161
Papapoulos SE (2016) Bone: romosozumab—getting there but not quite yet. Nat Rev Endocrinol 12(12):691–692
Barrett-Connor E, Siris ES, Wehren LE, Miller PD, Abbott TA, Berger ML, Santora AC, Sherwood LM (2005) Osteoporosis and fracture risk in women of different ethnic groups. J Bone Miner Res 20:185–194
Uitterlinden AG, Burger H, Huang Q, Yue F, McGuigan FE, Grant SF, Hofman A, van Leeuwen JP, Pols HA, Ralston SH (1998) Relation of alleles of the collagen type Ialpha1 gene to bone density and the risk of osteoporotic fractures in postmenopausal women. N Engl J Med 338:1016–1021
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
None.
Additional information
A response to these comments is available at doi 10.1007/s00134-017-3959-6.
Rights and permissions
About this article
Cite this article
Uzoigwe, C...E., Thimmaiah, R. & Eldessouky, A. Unmasking romosozumab. Osteoporos Int 28, 2019–2020 (2017). https://doi.org/10.1007/s00198-017-3958-7
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00198-017-3958-7